Heart Surgery with Liver Disease.
Liver disease — ranging from chronic hepatitis to decompensated cirrhosis — profoundly affects cardiac surgery risk. The liver is central to coagulation factor production, drug metabolism, and immune function, and its impairment creates a cascade of perioperative challenges. Coagulopathy from liver disease makes intraoperative bleeding more difficult to control. Impaired drug metabolism complicates anesthetic management. Portal hypertension increases the risk of splanchnic hypoperfusion during cardiopulmonary bypass. And the systemic inflammation of advanced liver disease contributes to multi-organ dysfunction in the postoperative period. The severity of liver disease, typically graded by the Child-Pugh classification (A, B, or C) or the MELD score, is the primary determinant of surgical risk. Patients with Child-Pugh A (compensated cirrhosis) can undergo cardiac surgery with modestly elevated risk. Patients with Child-Pugh C (decompensated cirrhosis) face prohibitive mortality — often exceeding 50% — and cardiac surgery is generally contraindicated unless it is part of a combined heart-liver transplant. The growing prevalence of non-alcoholic fatty liver disease (NAFLD) means that an increasing number of cardiac surgery patients have at least mild liver impairment, making preoperative liver assessment more important than ever.
What the evidence shows.
The most cited outcome data comes from a 2019 meta-analysis in the Annals of Thoracic Surgery analyzing over 4,000 cirrhotic patients who underwent cardiac surgery. Results showed 30-day mortality stratified by Child-Pugh class: Child-Pugh A: 7-10%, Child-Pugh B: 18-25%, Child-Pugh C: 40-67%. MELD score provided more granular risk prediction: MELD below 10 carried operative mortality similar to non-cirrhotic patients; MELD 10-15 had mortality of 15-20%; MELD above 20 had mortality exceeding 40%. Specific complications in cirrhotic patients include variceal bleeding (5-8%), hepatic decompensation (15-30%), coagulopathy requiring massive transfusion (20-35%), and prolonged ICU stay (average 8-14 days vs 2-3 days in non-cirrhotic patients). Cardiopulmonary bypass time and cross-clamp time were independent predictors of hepatic decompensation.
Current recommendations.
Current expert recommendations include: (1) comprehensive preoperative liver assessment including Child-Pugh score, MELD score, hepatic imaging, and hepatology consultation; (2) cardiac surgery is reasonable in Child-Pugh A patients with appropriate risk counseling; (3) cardiac surgery in Child-Pugh B patients should be approached with extreme caution and only at centers experienced with this population; (4) cardiac surgery is generally contraindicated in Child-Pugh C patients unless combined heart-liver transplant is planned; (5) off-pump CABG should be considered when feasible to avoid the hepatic insult of cardiopulmonary bypass; (6) catheter-based interventions (TAVR, PCI) should be preferred when they can achieve equivalent results with lower hepatic risk.
Why this matters for your decision.
Liver disease is sometimes discovered incidentally during cardiac surgery workup, and its significance may be underappreciated by surgical teams without hepatology expertise. A second opinion ensures that the severity of liver disease is properly staged, that operative risk is accurately communicated to the patient and family, and that catheter-based alternatives are considered when they could achieve equivalent cardiac outcomes with dramatically lower hepatic risk.
Need help with this decision?
Our Heart Team evaluates your specific situation with AI-augmented analysis and dual-physician review.